CPA
XFOR icon

Capital Performance Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

Capital Performance Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-25
Closed -$509 – 2734
2024
Q3 		$509 Buy
+25
New +$522 ﹤0.01% 2247

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Performance Advisors's XFOR Position: Q4 2024 in Review

Capital Performance Advisors sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 25 shares — an estimated $509 sold.

Capital Performance Advisors first reported a position in XFOR in Q3 2024 and held it in 1 quarter. The position peaked at $509 in Q3 2024. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Capital Performance Advisors reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 25 X4 Pharmaceuticals shares in Q4 2024, an estimated $509.
  • Capital Performance Advisors first reported a position in X4 Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's X4 Pharmaceuticals position peaked at $509 in Q3 2024.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.